tiotropium bromide: clinical use

Prescribing considerations

• Confirm that maintenance treatment—not acute bronchospasm relief—is intended.
• Assess, train and reassess inhalation technique and capsule-device handling.
• In moderate-to-severe renal impairment, use only when expected benefit outweighs potential risk.
• Use caution after a recent myocardial infarction, with unstable or clinically important arrhythmia, or after recent admission for severe heart failure.
• Minimise eye exposure and review persistent dry mouth because of dental-caries risk.

Contraindications and cautions

• Hypersensitivity to tiotropium, atropine or atropine derivatives such as ipratropium or oxitropium.
• Hypersensitivity to an excipient, including severe milk-protein allergy because the lactose may contain milk protein.
• Rare hereditary galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption for this lactose-containing product.

Monitoring

• Symptom control, exacerbations and rescue-inhaler reliance.
• Inhaler technique, adherence and ability to handle the Zonda device.
• Anticholinergic effects, particularly dry mouth, constipation, urinary retention, ocular symptoms and tachyarrhythmia.
• Renal function where impairment is known or suspected.
• Oral and dental health during persistent dry mouth.

Clinical pharmacology

Tiotropium is a quaternary ammonium, long-acting muscarinic antagonist. Reversible M3-receptor blockade reduces cholinergic bronchoconstriction; slow receptor dissociation supports prolonged bronchodilation. Its effect is primarily local in the airways, and absorbed medicine is predominantly eliminated renally.

Formulation and product differences

• The selected product contains inhalation-powder hard capsules intended exclusively for the Zonda device.
• Capsules are not oral dosage forms and must not be used in another inhaler.
• The capsules contain lactose monohydrate that may include trace milk protein.
• Device instructions are product-specific and should not be transferred from soft-mist or other capsule inhalers.

Inhaled preparation

Route: Inhaled

Strengths: 10 micrograms

Capsule

Route: Oral

Strengths: 18 micrograms